CRISPR Therapeutics AG (CRSP) EBT Margin (2016 - 2026)
CRISPR Therapeutics AG (CRSP) reported EBT Margin of 8373.94% for Q1 2026, up 721994.0% on a YoY basis from N/an in Q1 2025, and up 55.48% sequentially from 18810.88% in Q4 2025.
CRISPR Therapeutics AG (CRSP) EBT Margin (2016 - 2026) Analysis & Trends
CRISPR Therapeutics AG (CRSP) has 11 years of EBT Margin data on file, last reported at 8373.94% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin rose 721994.0% year-over-year to 8373.94%; the trailing twelve-month figure through Mar 2026 stood at 14567.32% (down 1462627.0% YoY), and the FY2025 full-year result was 17392.93%, down 1750343.0% from the prior year.
- EBT Margin climbed to 8373.94% in Q1 2026, from 18810.88% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 1029.07% in Q4 2024 to a low of 2000850.0% in Q4 2022.
- A 5-year average of 153619.05% and a median of 17137.84% in 2022 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin tumbled 199973750 bps in 2022 and soared 200089452 bps in 2023, its largest moves.
- Tracing CRSP's EBT Margin over 5 years: stood at 2000850.0% in 2022, then jumped by 100 bps to 44.52% in 2023, then jumped by 2211 bps to 1029.07% in 2024, then tumbled by 1928 bps to 18810.88% in 2025, then surged by 55 bps to 8373.94% in 2026.
- Business Quant data shows CRSP's EBT Margin at 8373.94% in Q1 2026, 18810.88% in Q4 2025, and 11903.49% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | CRISPR Therapeutics AG | 4.57 Bn | 2.12 Bn | - | -8,373.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8,373.94% |
| Dec 31, 2025 | -18,810.88% |
| Sep 30, 2025 | -11,903.49% |
| Jun 30, 2025 | -23,235.09% |
| Mar 31, 2025 | -15,593.87% |
| Dec 31, 2024 | 1,029.07% |
| Sep 30, 2024 | -14,130.56% |
| Jun 30, 2024 | -24,201.35% |
| Mar 31, 2024 | -22,989.48% |
| Dec 31, 2023 | 44.52% |
| Jun 30, 2023 | -109.74% |
| Mar 31, 2023 | -51.75% |
| Dec 31, 2022 | -2,000,850.00% |
| Sep 30, 2022 | -186,302.13% |
| Jun 30, 2022 | -113,744.30% |
| Mar 31, 2022 | -18,681.81% |
| Dec 31, 2021 | -1,112.50% |
| Sep 30, 2021 | -15,503.40% |
| Jun 30, 2021 | 84.75% |
| Mar 31, 2021 | -20,888.31% |